Charcot Marie Tooth Association • Founded in 1983 • Goals are patient support, public education, promotion of research and treatment for CMT • 2008, Change in research strategy – Focus on developing Rx for CMT – CMTA driven projects QuickTime™ and a decompressor are needed to see this picture.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Charcot Marie Tooth Association
• Founded in 1983• Goals are patient
support, public education, promotion of research and treatment for CMT
• 2008, Change in research strategy– Focus on developing Rx
for CMT– CMTA driven projects
QuickTime™ and a decompressor
are needed to see this picture.
• Physician Scientists– Michael Shy– Steven Scherer
• Lay Board Members– Pat Livney– Dave Hall– Gary Gasper– Elizabeth Ouellette– Herb Beron– Phyllis Sanders– Robert Kleinman– Jason Steinbaum– Vasi Vangelos– Steven O’Donnell
QuickTime™ and a decompressor
are needed to see this picture.
Experts in PNS Biology
• Ueli Suter : Professor and Chair in Cell Biology, Institute of Cell Biology, ETH Zurich
• Klaus Nave: Director, Max Planck Institute of Experimental Medicine
• Larry Wrabetz: Head, Myelin Biology Unit, San Raffaele Scientific Institute, Milan
• Laura Feltri: Head, NeuroGlia Unit, San Raffaele Scientific Institute, Milan
• Kris Jessen: Professor, University College London• Rhona Mirsky: Professor, University College London• Brian Popko: Professor, University of Chicago• David Colman, Director, Montreal Neurological Institute• Jack Griffin, Professor, Johns Hopkins
Historical Points
• NINDS sponsored Neuropathy Workshop-Oct 2006– Screen for compounds that reduced
PMP22 expression in CMT1A-high priority
• Meetings with Myelin Repair Foundation– Spring 2007– Partnership with Scientists and Industry
NINDS Meeting 2008
• Enthusiastic about projects to reduce PMP22 levels
• Approaches should include milestones • U Grant support potentially available to
help bring together scientists, industry and government if milestones met
Turn the science into therapy
• Present and Future strategies
• Focus on the most likely projects to be successful
• Choose the best people to perform the projects
• Set up the infrastructure to generate high quality clinical trials
QuickTime™ and a decompressor
are needed to see this picture.
Rational Approaches to Therapy
• FIND TREATMENTS NOW– Begin with CMT1A, the most
common form of CMT– High Throughput Screening– Network of CMT Centers
• FUTURE STRATEGIES– RNA interference (RNAi)– Gene transfer strategies
QuickTime™ and a decompressor
are needed to see this picture.
Duplication of PMP22 CMT1A (overexpression of the protein)
50 % of all CMT
Deletion of PMP22 HNPP (underexpression of the protein)
• FDA approved compound screen– Several thousand compounds– Preliminary hits in validation screen
• Non-FDA approved screen– Several hundred thousand compounds– Potential chemical modifications needed
• IMPORTANCE OF SECONDARY SCREENS & ANIMAL STUDIES
Project 3: Generate an improved laboratory model of CMT1A
• Klaus-Armin Nave• Director, Max Planck
Institute of Experimental Medicine, Gottingen, Germany
QuickTime™ and a decompressorare needed to see this picture.
QuickTime™ and a decompressor
are needed to see this picture.
Making a Reporter Rat
Dr. Klaus-Armin Nave
Project 4: How is human PMP22 regulated
• John Svaren, Department of Comparative Biosciences, U. of Wisconsin, Waisman Center
QuickTime™ and a decompressor
are needed to see this picture.
QuickTime™ and a decompressor
are needed to see this picture.
What regulates the mouse Pmp22 gene?
Dr.Ueli Suter
P1 P2
LMSE: late myelination Schwann cell-specific element
What regulates the mouse Pmp22 gene?
Dr. John Svaren
Krox20
Sox10
P1 P2
What regulates the human PMP22 gene?
Dr. John Svaren
Krox20
Sox10
P1 P2
CMTA Workshop: DEFINING THERAPEUTIC APPROACHES TO CMT2 November 10-12, 2010 San Diego, CA
* Draft program *
Wednesday, Nov 10, 2010 09.00 - 10.30 Overview of the workshop 09.00 – 09.15 Welcome, David Hall 09.15 - 09.30 STAR and CMTA, Pat Livney 09.30 – 12.30 Axonal degeneration, axonal transport, and trophic factors Rhona Mirsky & Zhigang He - moderators 09.30 – 10.00 Axons and axonal degeneration – Jack Griffin 10.00 – 10.30 Mechanisms of axonal degeneration – Marc Freeman 10.30 – 11.00 Coffee break 11:00 – 11.30 Axonal transport and disease - Erika Holzbaur 11.30 – 12.00 Trophic factors in neurons - David Ginty 12.00 – 12.30 Trophic factors as potential therapies - Ahmet Hoke 12.30 – 14.00 Lunch 14.00 – 16.00 How do faulty mitochondria cause CMT? Elena Rugarli & Bob Baloh - moderators 14.00 – 14.30 Overview of CMT2 – Stephan Zuchner 14.30 – 15.00 Mitochondria, mitofusin, and CMT - David Chan 14.00 – 15.30 GDAP1 and CMT - Ueli Suter 15.30 – 16.00 Panel discussion/Qs&As/Therapeutic strategies - Bob
Baloh, David Chan, Elena Rugarli, Ueli Suter, Stephan Zuchner
16.00-16.30 Coffee/Tea/snacks
16.30 - 18.30 Neurofilaments, axonal cytoskeleton, and CMT2E Michael Garcia & Yanmin Yang - moderators 16.30 -17.00 The biology of neurofilaments; Mouse models - Jean-Pierre Julien 17.00 - 17.30 Cellular models of CMT2E - Ron Liem 17.30-18.0 HSP and CMT - Vincent Timmerman
Valley of Death in Biomedical Research
QuickTime™ and a decompressor
are needed to see this picture.
CMT CENTERS OF EXCELLENCE
• Wayne State University, M Shy• University of Pennsylvania, R Finkel (CHOP)
and S Scherer (adults)• Johns Hopkins (A Hoke or C Sumner)• U. Washington (Seattle), T Bird• U of Rochester (MSG), D Herrman• U Tx (Southwestern) S Ianaconne (children)
Rare Disease Clinical Research Center
• NINDS/NORD
• Wayne State University, M Shy, C. Siskind, G. Acsadi• University of Pennsylvania, R Finkel (CHOP) and S Scherer
(adults)• National Hospital for Neurology & Neurosurgery, London, M.
Reilly, F. Muntoni• U. of Miami, S. Zuchner• U of Rochester (MSG), D Herrman, M. McDermott
TREAT-NMD and Datasets
• International patient registries for trials– Patient protected– Investigator Protected
• Advantages– Trials for rare forms of CMT– Concomitant trials for common forms like
CMT1A
TREAT-NMD and Datasets
• International patient registries for trials– Patient protected– Investigator Protected
• Advantages– Trials for rare forms of CMT– Concomitant trials for common forms like